Loading
A phase 1/2 trial of AVZO-1418 in biliary tract cancer, bladder & urothelial cancer and nasopharyngeal carcinoma, run by Avenzo Therapeutics, Inc., now recruiting.
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) is a phase 1/2 interventional study registered as NCT07038343 by Avenzo Therapeutics, Inc., with 480 participants planned, started 2025-06-04 and due to reach its primary completion in 2030-06. Interventions recorded: AVZO-1418, Combination Agent 1 and Combination Agent 2.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Avenzo Therapeutics, Bladder & urothelial cancer and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Bladder & urothelial cancer and the tag pipeline.
Shares Avenzo Therapeutics and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Bladder & urothelial cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Nasopharyngeal carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/